The firm said it expects to file an investigational new drug application for the autologous CAR T-cell therapy TPST-2003 in the US by the end of the year.

Wistar Institute scientists have designed a two-vaccine approach that not only targets the tumors’ unique molecular identity ...

Gothenburg, February 27, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next-generation cancer treatments based on its proprietary iTANK platform, tod ...

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR ...

UCB secured worldwide exclusive rights to develop, manufacture, and commercialize ATG-201, including access to Antengene’s enabling manufacturing technology for this bispecific T-cell engager modality ...

As interest in CAR T cells and immune-based oncology therapies increases, efficient phenotyping of cell therapy products ...

Neupharma will fund and conduct a pivotal clinical trial in Japan to support regulatory approval.

The U.S. government and academic labs are pushing multiple universal vaccine candidates through early clinical trials, targeting influenza strains and coronaviruses that mutate faster than today’s ...

Researchers at UAB have identified an immune pathway that might help explain why some women develop a serious pregnancy complication.

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today presented on its proprietary ...

Gothenburg, March 11, 2023 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells ...

Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) ...